Popular diabetes drug semaglutide under scrutiny for bone effects
NCT ID NCT07165158
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether semaglutide (a diabetes drug that lowers blood sugar and helps with weight loss) affects bone density and fracture risk in people with type 2 diabetes. About 150 adults aged 50–75 will get either semaglutide plus metformin or metformin alone for 12 months. Researchers will then compare bone density, fracture rates, and bone health markers between the two groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide combined with metformin
What this could lead to
If it works, this could show that semaglutide is safe for bones and may even help prevent fractures in people with type 2 diabetes.
What could go wrong
This is a small, early-phase trial (150 people) that hasn't started yet. The results may not apply to everyone, and weight loss from semaglutide could actually weaken bones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China